A 58-year-old man from Delhi presents to the emergency department with fever (39.2°C), dysuria, and flank pain for 3 days. He has a history of recurrent urinary tract infections treated with multiple antibiotics over the past 6 months. Urine culture grows a gram-negative rod identified as Escherichia coli. The organism is resistant to ceftriaxone and cefotaxime but susceptible to carbapenems and fluoroquinolones. ESBL testing by double-disk synergy test (DDST) is positive. Blood culture also yields the same organism. He is started on meropenem 1 g IV 8-hourly. After 72 hours of therapy, his fever persists, and repeat blood cultures remain positive. Susceptibility testing now shows resistance to meropenem as well, with MIC 8 µg/mL (breakpoint ≤2 µg/mL). What is the most likely mechanism of acquired carbapenem resistance in this isolate?

Explanation

## Clinical Context This case describes an ESBL-producing *E. coli* that initially responded to cephalosporin resistance but subsequently developed resistance to carbapenems during therapy — a phenomenon known as **heteroresistance** or **step-wise resistance acquisition**. ## Mechanism of Carbapenem Resistance in ESBL Producers **Key Point:** Carbapenem resistance in gram-negative bacteria, particularly in ESBL producers, is most commonly mediated by **metallo-β-lactamases (MBLs)**, especially in the Indian subcontinent where NDM-1 is endemic. ### Why Metallo-β-lactamase (MBL)? 1. **Broad spectrum activity**: MBLs (NDM-1, IMP, VIM, SPM) hydrolyze all β-lactams including carbapenems, with the exception of aztreonam. 2. **Zinc-dependent mechanism**: Unlike serine β-lactamases, MBLs require zinc cofactors for catalytic activity and are inhibited by EDTA and mercaptopropionic acid. 3. **Plasmid-mediated**: NDM-1 is typically carried on mobile genetic elements (plasmids, integrons), allowing rapid horizontal transfer — explaining the clinical deterioration despite appropriate initial therapy. 4. **Geographic prevalence**: NDM-1 is particularly common in *E. coli* isolates from India, Pakistan, and Southeast Asia [cite:Mandell, Douglas, and Bennett's Ch 214]. ### Why NOT the Other Options? | Mechanism | Why Incorrect in This Case | |-----------|----------------------------| | **Efflux pump + porin loss** | Causes reduced susceptibility (MIC 4–8 µg/mL) but is less common as sole mechanism in *E. coli*; typically seen in *Pseudomonas* and *Acinetobacter*. Does not explain the acute resistance emergence during therapy. | | **AmpC β-lactamase** | Confers resistance to cephalosporins but NOT to carbapenems; AmpC-producing organisms remain carbapenem-susceptible. | | **PBP mutations** | Chromosomal mutations are rare in *E. coli* and would not explain rapid resistance acquisition on a plasmid background. | ## Clinical Pearl **High-Yield:** The **step-wise resistance pattern** (ESBL → carbapenem-resistant) during therapy strongly suggests **horizontal gene transfer of a carbapenem-resistance determinant**, most commonly MBL in the Indian setting. This is why infection control and source control (e.g., urinary catheter removal, drainage of collections) are critical. ## Diagnostic Confirmation - **Modified Hodge test**: Positive (carbapenem hydrolysis). - **EDTA disk synergy**: Positive for MBL (inhibition by EDTA). - **Molecular PCR**: Detection of *bla*~NDM-1~, *bla*~IMP~, or *bla*~VIM~ genes. ## Management Implications **Mnemonic: MBL-CARE** - **M**etallo-β-lactamase confirmed → switch to colistin or tigecycline. - **B**road-spectrum coverage until susceptibilities known. - **L**aboratory confirmation (EDTA synergy, molecular). - **C**ontact precautions; infection control alert. - **A**void further carbapenem monotherapy. - **R**eassess source control (urosepsis → imaging for obstruction/abscess). - **E**arly infectious disease consultation.